|
|
???tair.name??? >
???browser.page.title.title???
|
Showing items 520441-520465 of 2348719 (93949 Page(s) Totally)
<< < 20813 20814 20815 20816 20817 20818 20819 20820 20821 20822 > >>
View [10|25|50] records per page
| 國立臺灣大學 |
1987 |
Interleukin 2 and Lymphokine-Activated Killer Cells in the Treatment of Childhood Primary Hepatocellular Carcinoma:A Preliminary Report
|
謝貴雄; Chang, J. S.; Wu, H. L.; Chu, C. T.; Hsieh, Kue-Hsiung; Chang, J. S.; Wu, H. L.; Chu, C. T. |
| 國立臺灣大學 |
1991 |
Interleukin 2 Therapy in Severe Atopic Dermatitis
|
謝貴雄; Chou, C. C.; Hsieh, Kue-Hsiung; Chou, C. C. |
| 臺大學術典藏 |
2021-08-19T10:23:39Z |
Interleukin 22 Expands Transit-Amplifying Cells While Depleting Lgr5 + Stem Cells via Inhibition of Wnt and Notch Signaling
|
Zha J.-M.; Li H.-S.; Lin Q.; WEI-TING KUO; Jiang Z.-H.; Tsai P.-Y.; Ding N.; Wu J.; Xu S.-F.; Wang Y.-T.; Pan J.; Zhou X.-M.; Chen K.; Tao M.; Odenwald M.A.; Tamura A.; Tsukita S.; Turner J.R.; He W.-Q. |
| 臺大學術典藏 |
2018-09-10T18:05:30Z |
Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease
|
Chin-Chung Shu and Jann-Yuan Wang and Ming-Fang Wu and Hsin-Chih Lai and Bor-Luen Chiang and Chong-Jen Yu; CHIN-CHUNG SHU; JANN-YUAN WANG |
| 臺大學術典藏 |
2018 |
Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease
|
Yu C.-J.; Chiang B.-L.; Lai H.-C.; Wu M.-F.; JANN-YUAN WANG; Shu C.-C. |
| 臺大學術典藏 |
2020-07-03T04:00:29Z |
Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease
|
Shu C.-C.;Wang J.-Y.;Wu M.-F.;Hsin-Chih Lai;Chiang B.-L.;Yu C.-J.; Shu C.-C.; Wang J.-Y.; Wu M.-F.; HSIN-CHIH LAI; Chiang B.-L.; Yu C.-J. |
| 臺大學術典藏 |
2021-06-29T08:39:13Z |
Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease
|
CHIN-CHUNG SHU; Wang J.-Y.; Wu M.-F.; Lai H.-C.; Chiang B.-L.; Yu C.-J. |
| 臺大學術典藏 |
2021-07-02T03:41:20Z |
Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease
|
Shu C.-C.; Wang J.-Y.; Wu M.-F.; Lai H.-C.; BOR-LUEN CHIANG; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:00:01Z |
Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease
|
Shu C.-C.; Wang J.-Y.; Wu M.-F.; Lai H.-C.; Chiang B.-L.; CHONG-JEN YU |
| 國家衛生研究院 |
2025-02-26 |
Interleukin 26 attenuates osteoblast differentiation in osteoarthritis patients by activating COX2 and NF-κB pathways
|
Lin, YH;Wang, YH;Peng, YJ;Liu, FC;Sytwu, HK;Cheng, CP |
| 國家衛生研究院 |
2023-04-19 |
Interleukin 26 induces macrophage IL-9 expression in rheumatoid arthritis
|
Wang, YH;Peng, YJ;Liu, FC;Lin, GJ;Huang, SH;Sytwu, HK;Cheng, CP |
| 國家衛生研究院 |
2020-04-10 |
Interleukin 26 skews macrophage polarization towards M1 phenotype by activating cJUN and the NF-kappaB pathway
|
Lin, YH;Wang, YH;Peng, YJ;Liu, FC;Lin, GJ;Huang, SH;Sytwu, HK;Cheng, CP |
| 國立臺灣大學 |
2012 |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu, Chen-Hua; Liang, Cheng-Chao; Liu, Chun-Jen; Tseng, Tai-Chung; Lin, Chih-Lin; Yang, Sheng-Shun; Su, Tung-Hung; Hsu, Shih-Jer; Lin, Jou-Wei; Chen, Jun-Herng; Chen, Pei-Jer; Chen, Ding-Shinn; Kao, Jia-Horng; 陳定信; 劉振驊; 高嘉宏; 蘇東弘; 徐士哲; 劉俊人; 陳培哲; 陳俊恒; 林昭維 |
| 臺大學術典藏 |
2018-09-10T09:23:42Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Chen, Jun-Herng; Chen, Pei-Jer; Chen, Pei-Jer; Chen, Ding-Shinn; Kao, Jia-Horng; Chen, Jun-Herng; Lin, Jou-Wei; Lin, Jou-Wei; Hsu, Shih-Jer; Hsu, Shih-Jer; Su, Tung-Hung; Su, Tung-Hung; JIA-HORNG KAO; Lin, Chih-Lin; Yang, Sheng-Shun; Yang, Sheng-Shun; Liu, Chen-Hua;Liang, Cheng-Chao;Liu, Chun-Jen;Tseng, Tai-Chung;Lin, Chih-Lin;Yang, Sheng-Shun;Su, Tung-Hung;Hsu, Shih-Jer;Lin, Jou-Wei;Chen, Jun-Herng;Chen, Pei-Jer;Chen, Ding-Shinn;Kao, Jia-Horng; Liu, C.-H., Liang, C.-C., Liu, C.-J., Tseng, T.-C., Lin, C.-L., Yang, S.-S., Su, T.-H., Hsu, S.-J., Lin, J.-W., Chen, J.-H., Chen, P.-J., Chen, D.-S., Kao, J.-H.; 陳定信 ;劉振驊 ;高嘉宏 ;蘇東弘 ;徐士哲 ;劉俊人 ;陳培哲 ;陳俊恒 ;林昭維; 陳定信 ;劉振驊 ;高嘉宏 ;蘇東弘 ;徐士哲 ;劉俊人 ;陳培哲 ;陳俊恒 ;林昭維; Liu, Chen-Hua; CHUN-JEN LIU; Liu, Chen-Hua; Liang, Cheng-Chao; PEI-JER CHEN; Liang, Cheng-Chao; Liu, Chun-Jen; Liu, Chun-Jen; CHEN-HUA LIU; Tseng, Tai-Chung; DING-SHINN CHEN; Tseng, Tai-Chung; Lin, Chih-Lin; TUNG-HUNG SU |
| 臺大學術典藏 |
2021-05-24T07:20:46Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
CHEN-HUA LIU; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:27Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:51Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:46Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; TUNG-HUNG SU; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 國立臺灣大學 |
2012 |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu, Chen-Hua; Liang, Cheng-Chao; Liu, Chun-Jen; Tseng, Tai-Chung; Lin, Chih-Lin; Yang, Sheng-Shun; Su, Tung-Hung; Lin, Jou-Wei; Chen, Jun-Herng; Chen, Pei-Jer; Chen, Ding-Shinn; Kao, Jia-Horng; 陳定信; 劉振驊; 高嘉宏; 蘇東弘; 劉俊人; 陳培哲; 陳俊恒; 林昭維 |
| 臺大學術典藏 |
2018-09-10T09:23:43Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu, Chen-Hua;Liang, Cheng-Chao;Liu, Chun-Jen;Tseng, Tai-Chung;Lin, Chih-Lin;Yang, Sheng-Shun;Su, Tung-Hung;Lin, Jou-Wei;Chen, Jun-Herng;Chen, Pei-Jer;Chen, Ding-Shinn;Kao, Jia-Horng; Liu, C.-H., Liang, C.-C., Liu, C.-J., Tseng, T.-C., Lin, C.-L., Yang, S.-S., Su, T.-H., Lin, J.-W., Chen, J.-H., Chen, P.-J., Chen, D.-S., Kao, J.-H.; 陳定信 ;劉振驊 ;高嘉宏 ;蘇東弘 ;劉俊人 ;陳培哲 ;陳俊恒 ;林昭維; 陳定信 ;劉振驊 ;高嘉宏 ;蘇東弘 ;劉俊人 ;陳培哲 ;陳俊恒 ;林昭維; Liu, Chen-Hua; Liu, Chen-Hua; CHUN-JEN LIU; Liang, Cheng-Chao; Liang, Cheng-Chao; PEI-JER CHEN; CHEN-HUA LIU; Liu, Chun-Jen; DING-SHINN CHEN; Tseng, Tai-Chung; TUNG-HUNG SU; Lin, Chih-Lin; Yang, Sheng-Shun; JIA-HORNG KAO; Su, Tung-Hung; Lin, Jou-Wei; Lin, Jou-Wei; Chen, Jun-Herng; Chen, Pei-Jer; Chen, Pei-Jer; Chen, Ding-Shinn; Kao, Jia-Horng; Kao, Jia-Horng |
| 臺大學術典藏 |
2021-07-03T03:34:28Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:51Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:46Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; TUNG-HUNG SU; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
Showing items 520441-520465 of 2348719 (93949 Page(s) Totally)
<< < 20813 20814 20815 20816 20817 20818 20819 20820 20821 20822 > >>
View [10|25|50] records per page
|
